Geode Capital Management LLC Acquires 47,969 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Geode Capital Management LLC grew its holdings in Sera Prognostics, Inc. (NASDAQ:SERA) by 8.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 586,837 shares of the company’s stock after acquiring an additional 47,969 shares during the period. Geode Capital Management LLC owned 1.76% of Sera Prognostics worth $4,578,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Quest Partners LLC lifted its stake in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics in the second quarter worth about $68,000. SG Americas Securities LLC bought a new stake in shares of Sera Prognostics during the 3rd quarter worth about $78,000. Prime Capital Investment Advisors LLC acquired a new position in shares of Sera Prognostics during the 3rd quarter valued at about $104,000. Finally, Jane Street Group LLC raised its stake in shares of Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after acquiring an additional 2,826 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Insiders Place Their Bets

In other news, insider Paul Kearney sold 4,078 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the transaction, the insider now directly owns 176,889 shares in the company, valued at $1,294,827.48. The trade was a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Benjamin Jackson sold 4,727 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $34,601.64. Following the completion of the sale, the general counsel now directly owns 135,528 shares of the company’s stock, valued at $992,064.96. This represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,154 shares of company stock valued at $206,087 in the last quarter. Insiders own 15.80% of the company’s stock.

Sera Prognostics Stock Performance

SERA opened at $8.02 on Monday. The firm has a market cap of $270.85 million, a P/E ratio of -8.10 and a beta of 0.92. The business has a 50 day moving average price of $7.47 and a 200 day moving average price of $7.25. Sera Prognostics, Inc. has a twelve month low of $4.90 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the firm earned ($0.23) EPS. As a group, analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.